X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA GLENMARK PHARMA ALEMBIC PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 24.8 24.5 101.4% View Chart
P/BV x 6.9 3.8 181.2% View Chart
Dividend Yield % 0.7 0.3 215.3%  

Financials

 ALEMBIC PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
GLENMARK PHARMA
Mar-17
ALEMBIC PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs792993 79.7%   
Low Rs443729 60.7%   
Sales per share (Unadj.) Rs167.0325.5 51.3%  
Earnings per share (Unadj.) Rs38.239.3 97.1%  
Cash flow per share (Unadj.) Rs42.048.7 86.3%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.2 279.0%  
Book value per share (Unadj.) Rs84.9159.2 53.3%  
Shares outstanding (eoy) m188.52282.17 66.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.72.6 139.7%   
Avg P/E ratio x16.221.9 73.8%  
P/CF ratio (eoy) x14.717.7 83.1%  
Price / Book Value ratio x7.35.4 134.4%  
Dividend payout %10.55.1 205.9%   
Avg Mkt Cap Rs m116,383242,991 47.9%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m4,21416,408 25.7%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m31,48791,857 34.3%  
Other income Rs m55374 14.7%   
Total revenues Rs m31,54292,230 34.2%   
Gross profit Rs m10,06020,367 49.4%  
Depreciation Rs m7222,644 27.3%   
Interest Rs m372,373 1.6%   
Profit before tax Rs m9,35615,724 59.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m2,1603,827 56.4%   
Profit after tax Rs m7,19411,088 64.9%  
Gross profit margin %31.922.2 144.1%  
Effective tax rate %23.124.3 94.9%   
Net profit margin %22.812.1 189.3%  
BALANCE SHEET DATA
Current assets Rs m15,06668,746 21.9%   
Current liabilities Rs m7,67427,027 28.4%   
Net working cap to sales %23.545.4 51.7%  
Current ratio x2.02.5 77.2%  
Inventory Days Days6785 78.8%  
Debtors Days Days4196 42.5%  
Net fixed assets Rs m8,23724,132 34.1%   
Share capital Rs m377282 133.6%   
"Free" reserves Rs m15,41644,643 34.5%   
Net worth Rs m16,00544,925 35.6%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m24,594117,639 20.9%  
Interest coverage x255.27.6 3,347.1%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.30.8 164.0%   
Return on assets %29.411.4 257.0%  
Return on equity %44.924.7 182.1%  
Return on capital %58.719.1 306.5%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81156,152 31.7%   
Fx outflow Rs m5,3188,084 65.8%   
Net fx Rs m12,49348,068 26.0%   
CASH FLOW
From Operations Rs m9,3046,574 141.5%  
From Investments Rs m-3,105-7,124 43.6%  
From Financial Activity Rs m-1,9595,432 -36.1%  
Net Cashflow Rs m4,2401,992 212.8%  

Share Holding

Indian Promoters % 74.1 48.3 153.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 6.9 42.0%  
FIIs % 9.1 34.4 26.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 56,727 87.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 21, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - SUN PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS